Parathyroid Drug on Hold; FreeStyle Libre Safety Note; Levothyroxine Overprescribed?
(MedPage Today) -- The FDA "identified deficiencies" in Ascendis Pharma's new drug application for its hypoparathyroidism drug palopegteriparatide (TransCon PTH), putting new labeling and post-marketing discussions on hold for now, the developer...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Endocrinology | Levothyroxine | Marketing | New Drug Applications | Pharmaceuticals | Synthroid